

General information about company	
Scrip code	953233
NSE Symbol	
MSEI Symbol	
ISIN*	INE663T07014
Name of company	SANDOR LIFE SCIENCES PRIVATE LIMITED
Type of company	
Class of security	Debt securities and/or non-cumulative redeemable preference shares
Date of start of financial year	01-04-2018
Date of end of financial year	31-03-2019
Date of board meeting when results were approved	30-05-2019
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	30-05-2019
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	Yearly
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited	Audited
Segment Reporting	Single segment
Description of single segment	Not Applicable
Start date and time of board meeting	30-05-2019 17:00
End date and time of board meeting	30-05-2019 19:00
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-10-2018	01-04-2018
B	Date of end of reporting period	31-03-2019	31-03-2019
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	143.32	459.685
	Other income	207.53	220.1
	Total income	350.85	679.785
2	Expenses		
(a)	Cost of materials consumed	0	0
(b)	Purchases of stock-in-trade	31.554	183.15
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0	0
(d)	Employee benefit expense	39.09	224.863
(e)	Finance costs	643.66	1328.19
(f)	Depreciation, depletion and amortisation expense	45.75	105.482
(f)	Other Expenses		
1	Other Expenses	89.87	203.381
10			
	Total other expenses	89.87	203.381

	Total expenses	849.924	2045.066
--	-----------------------	----------------	-----------------

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-10-2018	01-04-2018
B	Date of end of reporting period	31-03-2019	31-03-2019
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
3	Total profit before exceptional items and tax	-499.074	-1365.281
4	Exceptional items	0	0
5	Total profit before tax	-499.074	-1365.281
7	Tax expense		
8	Current tax	0	0
9	Deferred tax	0	0
10	Total tax expenses	0	0
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
14	Net Profit Loss for the period from continuing operations	-499.074	-1365.281
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
17	Net profit (loss) from discontinued operation after tax	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
21	Total profit (loss) for period	-499.074	-1365.281
22	Other comprehensive income net of taxes	0	0

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-10-2018	01-04-2018
B	Date of end of reporting period	31-03-2019	31-03-2019
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
23	Total Comprehensive Income for the period	-499.074	-1365.281
24	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
25	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
26	Details of equity share capital		
	Paid-up equity share capital	29.6	29.6
	Face value of equity share capital		
27	Details of debt securities		
28	Reserves excluding revaluation reserve		0
29	Earnings per share		
i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	16.86	46.12
	Diluted earnings (loss) per share from continuing operations	16.86	46.12

ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share		
	Basic earnings (loss) per share from continuing and discontinued operations	16.86	46.12
	Diluted earnings (loss) per share from continuing and discontinued operations	16.86	46.12
30	Debt equity ratio	0	0
31	Debt service coverage ratio	0	0
32	Interest service coverage ratio	0	0
33	Disclosure of notes on financial results		

Statement of Asset and Liabilities	
Particulars	Current year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2018
Date of end of reporting period	31-03-2019
Whether results are audited or unaudited	Audited
Nature of report standalone or consolidated	Standalone
Assets	
1	Non-current assets
Property, plant and equipment	73.966
Capital work-in-progress	
Investment property	
Goodwill	0
Other intangible assets	118.659
Intangible assets under development	
Biological assets other than bearer plants	
Investments accounted for using equity method	0
Non-current financial assets	
Non-current investments	3734.022
Trade receivables, non-current	
Loans, non-current	555.609
Other non-current financial assets	
Total non-current financial assets	4289.631
Deferred tax assets (net)	27.64
Other non-current assets	
Total non-current assets	4509.896

2	Current assets	
	Inventories	119.88494978585
	Current financial asset	
	Current investments	0
	Trade receivables, current	400.178
	Cash and cash equivalents	7.677
	Bank balance other than cash and cash equivalents	0
	Loans, current	0
	Other current financial assets	218.132
	Total current financial assets	625.987
	Current tax assets (net)	
	Other current assets	
	Total current assets	745.87194978585

Statement of Asset and Liabilities	
Particulars	Current year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2018
Date of end of reporting period	31-03-2019
Whether results are audited or unaudited	Audited
Nature of report standalone or consolidated	Standalone
3	Non-current assets classified as held for sale
4	Regulatory deferral account debit balances and related deferred tax Assets
	Total assets
	5255.76794978585
Equity and liabilities	
Equity	
Equity attributable to owners of parent	
	Equity share capital
	322.643
	Other equity
	-644.265
	Total equity attributable to owners of parent
	-321.622
	Non controlling interest
	Total equity
	-321.622
Liabilities	
Non-current liabilities	
Non-current financial liabilities	
	Borrowings, non-current
	3849.565
	Trade payables, non-current
	Other non-current financial liabilities
	Total non-current financial liabilities
	3849.565
	Provisions, non-current
	0

	Deferred tax liabilities (net)	
	Deferred government grants, Non-current	
	Other non-current liabilities	
	Total non-current liabilities	3849.565
	Current liabilities	
	Current financial liabilities	
	Borrowings, current	76.436
	Trade payables, current	144.35
	Other current financial liabilities	1068.859
	Total current financial liabilities	1289.645
	Other current liabilities	438.18
	Provisions, current	0
	Current tax liabilities (Net)	
	Deferred government grants, Current	
	Total current liabilities	1727.825
3	Liabilities directly associated with assets in disposal group classified as held for sale	0
4	Regulatory deferral account credit balances and related deferred tax liability	0
	Total liabilities	5577.39
	Total equity and liabilities	5255.768
	Disclosure of notes on assets and liabilities	

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results		
Particulars	3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-10-2018	01-04-2018
Date of end of reporting period	31-03-2019	31-03-2019
Whether accounts are audited or unaudited	Audited	Audited
Nature of report standalone or consolidated	Standalone	Standalone
1	Segment Revenue (Income)	
	(net sale/income from each segment should be disclosed)	
	Total Segment Revenue	
	Less: Inter segment revenue	
	Revenue from operations	
2	Segment Result	
	Profit (+) / Loss (-) before tax and interest from each segment	
	Total Profit before tax	
	i. Finance cost	
	ii. Other Unallocable Expenditure net off Unallocable income	
	Profit before tax	
3	(Segment Asset - Segment Liabilities)	
	Segment Asset	
	Total Segment Asset	
	Un-allocable Assets	
	Net Segment Asset	
4	Segment Liabilities	
	Segment Liabilities	

	Total Segment Liabilities		
	Un-allocable Liabilities		
	Net Segment Liabilities		
	Disclosure of notes on segments		

Independent Auditor's Report on Annual Financial Results of the Company Pursuant to the Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Sandor Lifesciences Private Limited


1. We have audited the annual financial results of Sandor Lifesciences private limited ('the Company') for the year ended 31st March 2019 ('financial results'), being submitted by the Company pursuant to the requirements of regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. Also, the figures up to the half year ended 31st March 2018 were neither audited nor reviewed. These financial results are based on the financial statements for the year ended 31 March 2019, prepared in accordance with the accounting principles generally accepted in India, including Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 ('the Act') and management certified financial results up to the half year ended 30th September 2018 prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, Interim Financial Reporting, specified under section 133 of the Act, and SEBI Circulars CIR/IMD/DF1/9/2015 dated 27 November 2015 and CIR/IMD/DF1/69/2016 dated 10 August 2016, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial results based on our audit of the financial statements for the year ended 31 March 2019 and management certified financial results for the half year ended 31st March 2019.
3. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
4. In our opinion and to the best of our information and according to the explanations given to us, the financial results:
 - (i) are presented in accordance with the requirements of regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circulars CIR/IMD/DF1/9/2015 dated 27 November 2015 and CIR/IMD/DF1/69/2016 dated 10 August 2016; and
 - (ii) give a true and fair view of the state of affairs as at 31 March 2019, and net loss (including other comprehensive income) and other financial information, in conformity with the accounting principles generally accepted in India including Ind AS specified under section 133 of the Act for the year ended 31 March 2019.
5. The financial results up to the half year ended 31st March 2019, as included in these financial results are based on management certified accounts and have not been subjected to review or audit (Also refer note x to these financial results).



A-418, Majestic Mansion, Shyamlal Buildings, Begumpet, Hyderabad-16.
Phone: 040-2776 1185 / 2776 9958, Mobile: +91 98480 43875
E-mail: knmurthyfca@gmail.com, Website: www.caknmurthy.com

6. Without modifying our report, we want to bring to the attention of stakeholders that there was a business sale, which happened on 3rd August, 2018, under which part of the business assets as well as liabilities were sold to a new company called Sandor Specialty Diagnostics Private Limited, in exchange for equity shares in the same.
7. The financial figures for the half year ended 31 March 2019 as reported in these financial results are the balancing figures between audited figures in respect of the full financial year and year to date figures for half year ended on 30th September 2018 which had only been reviewed by us and not subjected to audit. Our report is not modified in respect of this matter.

for KN Murthy & Co.,
Chartered Accountants,
(Firm Registration No. 006823S)



(KSVL Narasimha Murthy)
Proprietor
Membership No.203849



Place: Hyderabad
Date: 30thMay, 2019

Sandor

Lifesciences Pvt. Ltd.

"erstwhile SANDOR PROTEOMICS PVT LTD"

Corporate Identity No.: U85110TG2004PTC043672

8-2-326/5, 2nd Floor, Road No.3, Banjara Hills,

Hyderabad - 500 034. Telangana, INDIA.

Tel. : 040-2335 7047 to 51 and 2335 4824

Fax : 040-2335 7046

Email : info@sandor.co.in

Website : www.sandorlifesciences.co.in

Ref: SLSPL/BSE-2019/03

Date: 31st May 2019

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai – 400001

Dear Sir/Madam,


Sub: Declaration under Regulation 52(3) of SEBI(LODR) Regulation 2015, regarding Audit Report with unmodified opinion for the financial year 2018-19.

Pursuant to Regulation 52(3) of SEBI(LODR) Regulation 2015, as amended from time to time, we hereby declare that the Auditors of the Company M/s. KN Murthy and Co. Chartered Accountants, (Firm Reg. No. 0068235) have issued Audit Report with unmodified opinion for the Audited Annual Financial Results of the company for the financial year ended 31st March 2019.

You are requested to kindly take the above into records.

Thanking you

For and on behalf of
SANDOR LIFE SCIENCES PRIVATE LIMITED



(RAJEEV SINDHI)
Managing Director
(DIN: 00184701)

